Researchers identify new compounds for respiratory diseases
Wed Jun 26, 2019 | Section: Respiratory Disorders
Friedrich-Alexander-Universitaet Erlangen-Nuernberg, Stanford University and University of California, Oakland have presented new muscarinic M3 receptor antagonists reported to be useful for the treatment of asthma, chronic obstructive pulmonary disease, bronchopulmonary dysplasia and urinary incontinence. An exemplified compound inhibited the binding of [3H]-N-methylscopolamine to human M3 receptor expressed in membrane of transfected HEK-293 cells (Ki < 1 nM) with selectivity over M2 receptors in radioligand competitive binding assays (WO 2019110521).